jRCT2080224729: A PHASE I STUDY OF ERY974 AS A SINGLE AGENT IN PATIENTS WITH GPC3-POSITIVE ADVANCED SOLID TUMORS |
|
|
| Recruiting | 1 | 39 | Japan | ERY-974 - Roche, Actemra IV (tocilizumab) - Roche, JW Pharma | Chugai Pharmaceutical Co., Ltd. | Advanced/recurrent solid tumors | | | | |
NCT05022927: A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 179 | Japan, RoW | ERY974, Tocilicumab, Atezolizumab, Bevacizumab | Chugai Pharmaceutical | Hepatocellular Carcinoma (HCC) | 12/25 | 12/25 | | |
